Cancer Metastases and Clinical Therapies

Da-Yong Lu*, Ting-Ren Lu and Shan Cao

1College of Science, Shanghai University, Shanghai 200444, PR China
2Zhong-Guo High School, Xu-Hui District, Shanghai, PR China

Abstract

More than 90% cancer deaths are caused by cancer metastasis. As cancer metastasis is the main cause of human deaths, we shall pay more attentions on it. Currently, treatment and chemotherapy are focused on primary tumors rather than metastatic processes. Antimetastatic drugs are often used as assistant therapy. So cancer patients' survivals have been improved very little. To change this mindset, we highlight this problem by giving new perspectives and try to improve the outcome of chemotherapy of cancer patients from different possible ways. Human cancer metastasis is a long-evolving, multi-steps process that can only be treated or controlled by drugs or immuno-modulators by now. Human neoplasm metastasis, at least a month-long course, encompasses several different substages and affects or being affected by numerous genes and molecules. We have found that each drug or immuno-modulator might act differently within the various stages of a thorny problem. We, therefore, suggest that future antimetastatic therapy should be strategically optimized according to characteristics of metastatic processes in order to reach maximum therapeutic benefits. In this view, we propose, address and support this issue by using past literature evidence, our experimentation and existing biological, anatomical and pathologic characteristics.

Present Clinical Antimetastatic Therapy

Present antimetastatic therapies are overwhelmed with researches and applications of antivascular (angiogenesis) and matrix metalloproteinase (MMPs) inhibitors and more than 500 related-agents of different chemical formulae have been literally reported. Currently all FDA licensed or internationally available antimetastatic drugs are generally consisted with these two types [2-5]. However, these drugs are far from satisfactory in clinics for the reasons of indiscriminate molecular inhibitions and generally low survival benefits for patients. Paradoxically to our efforts and expectations, except some antibodies, no obvious improvements and therapeutic benefits by conventional antimetastatic drugs (usually antivascular agents or MMPs inhibitors) have been achieved until now. Therapeutic benefits in late-staged or aged cancer patients are especially poor and useless [6-7]. More important, some unfavorable evidence against angiogenesis inhibitors to metastasis has been reported [8-10]. Clinical anticancer drug therapies currently in use have been mainly focusing on primary tumor growth rather than specifically targeting pathologic courses of metastases relevantly. Finding important drugs targeting specifically to neoplasm metastases is essential and indispensable [1, 11-13]. It nevertheless needs changing our focus from targeting vascularity and MMPs into more metastatic-relating molecules. So how to optimistically use drugs in antimetastatic treatments remains to be a great challenge.

Shall Antimetastatic Drugs Offer to All Cancer Patients?

Cancer metastases do not occur in all patients. 60% patients suffer those tumor types with low metastatic rates [14]. These patients will have good survival expectancy. To those patients, there is no need of additional antimetastatic therapy. Only operations or therapy targeting primary tumors are enough. However, in many cases, we cannot know if a specific individual will metastasize or not? Or we have already found metastasized tumors when patients are diagnosed with cancer. There are two main types of options we can choose; (i) find out if some metastatic gene signatures in primary tumors [11,15,16]; (ii) treatment of metastatic foci with high active drugs. This is the central problem discussing in the following sections (Table 1).

Shall human tumor metastasis be treated according to clinical situations?

Present antimetastatic therapy regards patients equally. No specific attentions are paid according to clinical situations of patients. Tumor metastases involve a fixed course of pathophysiological processes [11,17,18]. Human cancer metastasis encompasses several different substages (1) invade locally through surrounding extracellular matrix (ECM) and stromal cell layers, (2) intravasate and travel to the lamina of blood vessels; (3) tumor cells survive the rigors of transport through the vasculature; (4) arrest at distant organ sites; (5) tumor cell extravasate...
into the parenchyma of distant tissues; (6) initially survive in these foreign microenvironments in order to form micrometastases, and (7) reinitiate their proliferative programs at distant sites, thereby generating macroscopic, clinically detectable neoplastic growths [11, 17-21]. From this pathologic point of view, since a metastasis must travel more than one body-organ, the obvious different anatomic organs may possibly trigger different molecules and pathways linking neoplasm metastases. This reasonably results in being affected or inhibited with different types of drugs in different stage (Table 2). In return, different anticancer drugs will certainly not act in the same in all metastastic organs [17,18].

We previously hypothesize that many anticancer or antimetastatic drugs might act differently in these different courses of substages and could be wisely applied of drugs according to metastatic cascade. Bisdioxopiperazine compounds (Biz), including ICRF-154, Razoxane (ICRF-159, Raz), ICRF-186 and ICRF-187 (two stereo-isomers of Raz) and ICRF-193, developed in the UK, has been a series of serendipitous agents found to be significantly effective against a model of spontaneous metastasis (Lewis lung carcinoma, 3LL) [22,23]. Ever since their development in 1969, new analogs Probimane and Bimolane were synthesized at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China [24]. In order to testify this hypothesis, we carried out an experiment by comparing the different drug inhibitions against a spontaneous metastatic model, Lewis lung carcinoma (3LL), which contains all processes of human metastasis cascade. Our work showed that Pro and Bim significantly inhibited the pulmonary metastasis of 3LL both following day2 and day8 injections, but Raz only significantly inhibited the pulmonary metastasis of 3LL following day2 injections. Pro inhibited the pulmonary metastasis of 3LL more potently than Bim did at equitoxic dosage. Comparatively, it seems that Pro has superior inhibition of pulmonary metastasis of 3LL than Bim and Raz for its exclusive targeting potentiality [17].

From the report of James et al, the detachment of 3LL began at day 6-8 [25]. Our study supports that Raz only is highly effective against tumor detachments yet ineffective against the formed metastatic foci. This data can be used to explain also why Raz was reported to be more effective against neoplasm metastases for spontaneous metastatic tumors rather than for artificial ones [3]. However, Pro and Bim might be equally effective in both d2 and d8 treatment schedules. From our early data of 14C-probimane tracing and autoradiography [26], an obvious greater accumulation of Pro was found in metastatic tissues. It can help to explain that Pro can more effectively inhibition of neoplasm metastasis than Raz in formed metastatic foci through stronger antiproliferative effect [27].

In general, we propose that the MMPs inhibitors might be more active in preventing tumor cells from detaching from primary locations. Immuno-modulators might promote the activity of macrophages in killing tumor cells during the vascular and lymphatic circulations [28,29]. Angiogenesis inhibitors might be used as the substage of attaching of tumor cells to remote organs and micrometastasis formation. However, highly cytotoxicity agents might be more effective in treatment of formed metastatic foci and preference-organs [18].

Find more metastatic-related molecules

Current antimetastatic therapies rely heavily on angiogenesis or MMPs inhibitor. Since tumor metastasis is so complex a process that triggers more than 100 molecules, other metastatic-related molecules such as sialic acids [30-36] might be also very useful in antimetastatic therapy. We need to strengthen these researches.

Sialic acids (Sias, neuraminic acid) are a special series of 9-carbon backbone acidic carbohydrates and typically found at outermost part of sugar chains attached to cell membrane macromolecules. They play many important roles in a series of physiological and pathologic processes, including microbe binding that leads to infections, regulation of the immune response, the progression and spread of human malignancies and in certain aspects of human evolution. The earliest work tackling the phenomenon of a positive relationship between sias and tumors can be traced back to Kimura et al from 1958. Their discovery is tumor cells might excrete and contain more sialyl glycoproteins or glycolipids. These characteristic later have been found to link with highly metastatic tumor types [16]. It has been shown that there are higher sias contents in highly metastatic tumor cell lines than those in lower metastatic tumor cell lines. Since then, numerous similar reports and reviews have been published rapidly. Many researchers have also showed patients with tumors of high levels of sialyl Lewis X or sialyl Tn antigens appear to be linked with poor prognosis of patients which is one of the most conspicuous pathologic features of sias in tumors clinically. Many relationships between neoplasm metastasis and sia aberration can be seen from references and I shall not reemphasized them here. These pathways should be regarded as an important target for drug therapies [30-33]. Other new drug targets are also given [34-37].

To conclude, the decision of antimetastatic treatment should be better based on the stage of a metastasis in patients. It might broaden present customs of finding antimetastatic drugs only into clinical drug option strategy as a complementary and perfection of individualized cancer chemotherapy [38,39].

Concluding Remarks

Since tumor metastasis is the main cause of cancer patients and current clinical therapeutic options are unsatisfactory, thus we need to pay more attentions on these researches and update our ideas on this matter. Since the population of cancer patients is so large, if we adhere these researches and any improvements in metastatic therapy will save tremendous life. Let’s hope the best.

References

1. Lu DY, Lu TR (2010) Antimetastatic activities and mechanisms of bisdioxopiperazine compounds. Anticancer Agents Med Chem10: 564-570.
2. Taraboletti G, Margosio B (2001) Antiangiogenic and antivascular therapy for cancer. Curr Opin Pharmacol 1: 378-384.

3. Sava G, Bergamo A (1999) Drug control of solid tumour metastases: a critical view. Anticancer Res 19: 1117-1124.

4. Lu DY, Huang M, Zhou J, Ding J (2006) recent advances in anti-metastatic drug development. Acta Pharmacol Sin 27: 66-67.

5. Folkman J (2006) Angiogenesis. Annual Rev Med 57: 1-18.

6. Varmus H (2006) The new era in cancer research. Science 312: 1162-1165.

7. Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer Statistics, 2006. CA Cancer J Clin 56: 106-130.

8. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, et al. (2009) Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.

9. Ebos JML, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, et al. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15: 232-239.

10. Verheul HM, Pinedo HM (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nature Rev Cancer 7: 475-485.

11. Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147: 275-292.

12. Dong F, Budhu AS, Wang XW (2009) Translating the metastasis paradigm from scientific theory to clinical oncology. Clin Cancer Res 15: 2588-2593.

13. Mina LA, Sledge GW Jr (2011) Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol 8: 325-332.

14. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236.

15. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.

16. Wang W, Goswami S, Lapidus K, Wells AL, Wyckoff JB, et al. (2004) Identification and testing of a gene expression signature of invasive carcinoma cells within primary mammary tumors. Cancer Res 64: 8585-8594.

17. Lu DY, Wu FG, Zhen ZM, Lu TR, Wu HY, et al. (2010) Different spontaneous pulmonary metastasis inhibitions against Lewis lung carcinoma in mice by bisdioxopiperazine compounds of different treatment schedules. Sci Pharm 78: 13-20.

18. Lu DY, Yi YC (2012) Antimetastatic therapies according to metastatic cascade. Adv Pharmacoepidemiology & Drug Safety 1: e107.

19. Poste G, Fidler IJ (1980) The pathogenesis of cancer metastasis. Nature 283: 139-146.

20. Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: Twenty-eight G.H.A. Cloves memorial awards lecture. Cancer Res 50: 6130-6138.

21. Klein CA (2008) Cancer. The metastasis cascade. Science 321: 1785-1787.

22. Hellmann K, Burange K (1969) Control of malignant metastases by ICRF-159. Nature 224: 273-275.

23. Herman EH, Wiltik DT, Hellmann K, Waravdekar VS (1982) Biological properties of ICRF-159 and related Bis(dioxopiperazine) compounds. Adv Pharmacol Chemother 19: 249-290.

24. Lu DY, Lu TR (2010) Anticancer activities and mechanisms of bisdioxopiperazine compounds probimane and MST-16. Anticancer Agents Med Chem 10: 78-91.

25. James SE, Salsbury AJ (1974) Effect of (±)-1,2-bis(3,5-dioxopiperazin-1-yl) propane on tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma. Cancer Res 34: 839-842.

26. Lu DY, Chen RT, Lu TR, Wu HY, Qu RX, et al. (2010) The absorption, distribution and excretion of 14C-probimane. Sci Pharm 78: 445-450.

27. Lu DY, Huang M, Xu CH, Yang WY, Hu CX, et al. (2005) Anti-proliferative effects, cell cycle G,M phase arrest and blocking of chromosome segregation by probimane and MST-16 in human tumor cell lines. Bmc Pharmacol 5: 11.

28. Fidler IJ (1985) Macrophages and metastasis—a biological approach to cancer therapy. Cancer Res 45: 4714-4726.

29. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, et al. (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791.

30. Lu DY, Cao JY (2001) Structural aberrations of cellular sialic acids and their functions in cancer metastases. Journal of Sanghal University 5: 164-170.

31. Lu DY, Lu TR, Wu HY (2011) Antimetastatic therapy targeting aberrant sialylation profiles in cancer cells. Drugs and Therapy Studies 1.

32. Lu DY, Lu TR, Wu HY (2012) Development of antimetastatic drugs by targeting tumor sialic acids. Sci Pharm.

33. Xi YC, Lu DY (2012) The relationship between tumor sialic acids and neoplasm metastasis and as a drug target. Cell Dev Biol 1.

34. Vetvicka V, Fusek M (2012) Proctacathpin D as a tumor marker, anti-cancer drug or screening agent. Anticancer Agents Med Chem 12: 172-175.

35. Chen L, Yang S, Jakonic J, Zhang J, Huang XY (2010) Migrastatin analogues target fascin to block tumor metastasis. Nature 464: 1062-1066.

36. Lu da Y, Chen XL, Ding J (2007) Treatment of solid tumors and metastases by fibroinogen-targeted anticancer drug therapy. Med Hypotheses 68: 188-193.

37. Lu da Y, Lu TR, Ding J (2010) Cell biological manifestations of Bisdioxopiperazines: treatment of human tumor cell lines in culture. Anticancer Agents Med Chem 10: 657-660.

38. Lu da Y, Chen XL, Ding J (2006) Individualized cancer chemotherapy integrating drug sensitivity tests, pathological profile analysis and computational coordination—an effective strategy to improve clinical treatment. Med Hypotheses 66: 45-51.

39. Lu DY, Lu TR, Chen XL (2012) Individualized cancer chemotherapy, are we ready for that yet? Metabolomics 2: e113.